A Study to Establish Proof-of-Biology for MK0646 in Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Dalotuzumab will induce a decrease in the growth factor signature.
Following single dose of study drug infused over 60 - 120 minutes
No
Medical Monitor
Study Director
Merck
United States: Food and Drug Administration
2008_554
NCT00759785
October 2008
February 2010
Name | Location |
---|